Hans Christinger Joins Innovus Pharma's Advisory Board

SAN DIEGO, CA--(Marketwired - Nov 2, 2015) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, has announced today the addition of Mr. Christinger to the Company's Advisory Board. Mr. Christinger is currently Vice President, Business Development and Alliance Management at Ophthotech Corporation. Mr. Christinger has served in various roles leading business development and corporate development during his career at Abbott, Roche and Vertex.

Dr. Bassam Damaj, Ph.D., Chief Executive Officer, said, "We are extremely pleased that Mr. Christinger will be on hand to advise Innovus as we execute our aggressive growth plans over the next several years. His long experience in licensing & acquisitions in bio-pharmaceutical companies such as Ophthotech, Abbott, Roche and Vertex will be invaluable to us and to our business strategy."

Mr. Christinger brings 24 years bio-pharmaceutical experience, primarily focused on partnering, licensing (in- and out), and acquisitions (products and companies) as well as divesting products. Mr. Christinger has been based both in the US and abroad and has extensive ex-US experience. He has established and led teams enabling numerous global transactions as well as regional and local deals across more than 30 markets in emerging and developed markets.

Mr. Christinger began his career as a scientist at Genentech where he authored 15 structural biology related, peer-reviewed papers. He earned a Master of Business Administration from Babson College, a Master of Science in Chemistry from San Francisco State University and a Bachelor of Science in Biochemistry from the University of Vermont.

Currently Innovus's Advisory Board is comprised of Mr. Robert Hoffman, Chief Financial Officer of Anaptys, Inc. in San Diego and the former CFO of Arena Pharmaceuticals.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products Zestra® for female arousal and EjectDelay® for premature ejaculation and has a total of five marketed products in this space, including Sensum⁺® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), Zestra Glide®, Vesele® for promoting sexual and cognitive health, Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com

Innovus Pharma's Forward-Looking Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority relating to Androferti, to successfully commercialize such products and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.